Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus neoadjuvant anthracycline/nab-paclitaxel chemotherapy in primary invasive triple-negative breast cancer
2016-004734-22Phase 3Completed
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atezolizumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Roche. Primary endpoint: Pathologic complete response (pCR). Started May 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-004734-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004734-22.